CINECA IRIS Institutional Research Information System

CHIRICOZZI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.121
AS - Asia 3.385
EU - Europa 2.179
SA - Sud America 468
AF - Africa 219
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 6
Totale 14.390
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.916
SG - Singapore 1.015
CN - Cina 959
HK - Hong Kong 632
IT - Italia 455
BR - Brasile 386
GB - Regno Unito 349
VN - Vietnam 314
BG - Bulgaria 302
SE - Svezia 250
DE - Germania 148
CI - Costa d'Avorio 146
RU - Federazione Russa 146
FR - Francia 144
CA - Canada 143
FI - Finlandia 133
TR - Turchia 92
IN - India 81
JP - Giappone 81
AT - Austria 60
MX - Messico 43
NL - Olanda 35
LT - Lituania 31
BD - Bangladesh 29
IE - Irlanda 27
IQ - Iraq 25
AR - Argentina 24
PK - Pakistan 23
ES - Italia 21
ID - Indonesia 20
SN - Senegal 19
SA - Arabia Saudita 17
PH - Filippine 15
CO - Colombia 14
PL - Polonia 13
UZ - Uzbekistan 13
CH - Svizzera 12
EC - Ecuador 11
EG - Egitto 11
AU - Australia 10
MA - Marocco 10
UA - Ucraina 10
CL - Cile 9
HU - Ungheria 9
ZA - Sudafrica 9
BJ - Benin 8
MY - Malesia 8
RO - Romania 8
IL - Israele 7
VE - Venezuela 7
JO - Giordania 6
KR - Corea 6
PE - Perù 6
BO - Bolivia 5
GE - Georgia 5
NP - Nepal 5
OM - Oman 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
BE - Belgio 4
GR - Grecia 4
HN - Honduras 4
JM - Giamaica 4
PY - Paraguay 4
BB - Barbados 3
EU - Europa 3
KE - Kenya 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LB - Libano 3
PS - Palestinian Territory 3
AL - Albania 2
BY - Bielorussia 2
DZ - Algeria 2
ET - Etiopia 2
IR - Iran 2
MT - Malta 2
NZ - Nuova Zelanda 2
PA - Panama 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
UG - Uganda 2
UY - Uruguay 2
AO - Angola 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
HR - Croazia 1
KH - Cambogia 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
ML - Mali 1
NE - Niger 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
Totale 14.380
Salva come PNG Salva come JPEG
Città #
Ashburn 964
Fairfield 838
Woodbridge 678
Hong Kong 625
Singapore 561
Santa Clara 545
Houston 483
Ann Arbor 432
San Jose 398
Seattle 350
Chandler 307
Sofia 300
Cambridge 293
Beijing 278
Wilmington 273
Shanghai 250
Lancaster 227
New York 217
Dallas 168
Abidjan 145
Princeton 129
Boardman 122
Lawrence 111
Medford 107
Ottawa 101
Los Angeles 100
Lauterbourg 99
Serra 99
Des Moines 90
Council Bluffs 64
Nanjing 61
Istanbul 60
Dong Ket 59
London 51
Redondo Beach 48
San Diego 44
Ho Chi Minh City 43
Guangzhou 42
Tokyo 41
Florence 40
Helsinki 39
Vienna 38
Buffalo 37
Hanoi 34
Redwood City 34
Washington 33
Dearborn 31
Phoenix 31
Frankfurt am Main 29
Munich 26
Milan 24
São Paulo 24
Chicago 22
Siauliai 22
Düsseldorf 20
Rome 20
Dakar 19
Nanchang 19
Rio de Janeiro 19
Turku 17
Amsterdam 16
Changsha 16
Kunming 15
Montreal 15
Orem 15
Atlanta 13
Belo Horizonte 13
Jiaxing 13
Brooklyn 12
Nuremberg 12
Paris 12
Tashkent 12
Hebei 11
Shenyang 11
Toronto 11
Norwalk 10
Baghdad 9
Bremen 9
Chennai 9
Detroit 9
Hangzhou 9
Cotonou 8
New Delhi 8
San Francisco 8
Bologna 7
Cairo 7
Dhaka 7
Fuzhou 7
Porto Alegre 7
Boston 6
Brasília 6
Budapest 6
Campinas 6
Da Nang 6
Guayaquil 6
Hefei 6
Jinan 6
Kent 6
Lima 6
Lucca 6
Totale 10.758
Salva come PNG Salva come JPEG
Nome #
Trattamento topico delle dermatiti da contatto: validazione scientifica di una crema lenitiva a base di biotina, L-carnitina, pantenolo, α-bisabololo e tocoferolo. [Topical treatment of contact dermatitis with natural active principles] 257
Assessment of disease severity and treatment effectiveness in hidradenitis suppurativa 234
Sensors and Biosensors for C-Reactive Protein, Temperature and pH, and Their Applications for Monitoring Wound Healing: A Review 215
Potential correlation of wound bed score and biomarkers in chronic lower leg wounds: an exploratory study 195
AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa 185
Complete Resolution of Erythrodermic Psoriasis in an HIV and HCV Patient Unresponsive to Antipsoriatic Treatments after Highly Active Antiretroviral Therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir). 174
Nanomedicine in dermatology: Benefits and emerging applications 171
Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. 169
Alexithymia affects patients with hidradenitis suppurativa 167
Optimizing acitretin use in patients with plaque psoriasis 165
Improvement of severe facial seborrheic dermatitis following low-dose isotretinoin therapy 164
Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris 163
The Quality of Life impairment in Hidradenitis Suppurativa 162
Acne fulminans associated with lymecycline intake: A case report 161
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis 158
Risankizumab for the treatment of moderate to severe psoriasis 156
Gynecomastia following isotretinoin treatment: a rare endocrine side effect 155
Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry 155
Long-Term Outcome of Adalimumab in a Young Girl with Hidradenitis Suppurativa 154
TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand 153
Deep pulse fractional CO2 laser combined with a radiofrequency system: results of a case series 152
Spotlight on dupilumab in the treatment of atopic dermatitis: Design, development, and potential place in therapy 152
A new therapeutic for the treatment of moderate to severe plaque psoriasis: apremilast 149
IL-6 as a druggable target in psoriasis: Focus on pustular variants 149
UVA-1 Laser in the Treatment of Palmoplantar Pustular Psoriasis 148
Apremilast for the treatment of psoriasis 147
Isotretinoin-triggered acne fulminans: a rare, disabling occurrence 147
Biomarkers for psoriasis skin lesions 146
Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis 143
A giant annular rash in a tuscanian woodman: the many faces of erythema chronicum migrans 142
Atopic dermatitis keratinocytes exhibit normal T(H)17 cytokine responses 141
A revolutionary therapeutic approach for psoriasis: bispecific biological agents. 141
Relevance of in vitro 3-D skin models in dissecting cytokine contribution to psoriasis pathogenesis 138
A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents 138
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis. 137
Pathogenic role of IL-17 in psoriasis and psoriatic arthritis 137
HIDRAdisk: an innovative visual tool to assess the burden of hidradenitis suppurativa 137
Cutaneous human papillomaviruses as recurrence factor in actinic keratoses 136
Profile of certolizumab and its potential in the treatment of psoriatic arthritis. 136
Scanning the immunopathogenesis of psoriasis 134
New insights in the pathogenesis of cutaneous autoimmune disorders. 134
Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. 134
Gene Expression Profiling Associated with the Progression of Classic Kaposi’s Sarcoma. 133
Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus 132
Potential role of serum amyloid A in hidradenitis suppurativa 132
Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis 132
Tofacitinib for the treatment of moderate-to-severe psoriasis 131
Efficacy and safety of Infliximab in psoriatic patients over the age of 65 130
Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel 130
Lasers and Energy Devices for the Skin: Conventional and Unconventional Use 130
Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments 129
Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015) 128
Effective topical agents and emerging perspectives in the treatment of psoriasis. 128
Integrative responses to IL-17 and TNF-a in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. 128
Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk. 128
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers. 126
The management of moderate-to-severe chronic plaque psoriasis 126
Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target? 125
PsAPASH: A new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition 125
Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. 124
Thymic stromal lymphopoietin links keratinocytes and dendritic cell-derived IL-23 in patients with psoriasis 124
Unconventional Use of Intense Pulsed Light 124
Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics 123
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis 123
New topical treatments for psoriasis 122
Trattamento topico della xerosi cutanea severa: risultati di uno studio osservazionale. [Topical treatment of severe xerosis: Results of an observational study] 121
Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy 121
Ustekinumab for treatment of plaque psoriasis in patient with Down Syndrome. 121
Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept 121
Characterization of comorbid conditions burdening hidradenitis suppurativa: a multicentric observational study 120
The new era for the treatment of psoriasis and psoriatic arthritis: Perspectives and validated strategies. 119
Emerging applications of nanomedicine in dermatology 119
Apheresis in the treatment of recalcitrant atopic dermatitis: Case series and review of the literature 118
IL-17 targeted therapies for psoriasis. 116
IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model. 116
Granuloma annulare: A case treated with infliximab successfully 116
Testing biologics and intracellular signaling inhibitors on pediatric atopic dermatitis: a stairway to modern therapeutic approaches 116
Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. 115
Biomolecular index of therapeutic efficacy in psoriasis treated by anti-TNF alpha agents 115
Immunologic biomarkers for clinical and therapeutic management of psoriasis 115
No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents 115
An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis 113
Urticaria associated with hyper-IgE in a patient with psoriasis undergoing treatment with efalizumab. 113
Adipose tissue response to IL-17 combined with TNF-alpha exposure 113
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: Results of a single-centre, retrospective study 112
Elderly psoriatic patients under biological therapies: an Italian experience 112
Hidradenitis suppurativa: guidelines of the Italian Society of Dermatology and Venereology (SIDeMaST) for the use of anti-TNF-α agents 111
Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy 111
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris. 110
Un nuovo approccio fototerapico alle dermatosi croniche 110
HS-TIME: A Modified TIME Concept in Hidradenitis Suppurativa Topical Management 108
Genetic Markers for Cardiovascular Disease in Psoriasis: The Missing Piece. 107
Dusky Red Swelling of the Penis in Association with Fever and Diarrhoea: A Quiz. 107
European consensus statement on phenotypes of pustular psoriasis 107
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases. 106
Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study 103
Vitiligo treatment with Monochromatic Excimer Light and Tacrolimus: results of an open randomised controlled study. 102
The Hidradenitis Suppurativa (HS) “Multidisciplinary Unit”: a rationale and practical proposal for an organised clinical approach 102
Psoriasis 100
Use of Vitamins and their Derivates in the Treatment of Cutaneous Disorders. 98
Totale 13.493
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.286
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.286
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.112 23 42 46 65 230 159 21 81 42 16 45 342
2022/20231.155 159 166 80 62 110 117 16 83 258 5 82 17
2023/2024768 36 39 90 30 110 243 20 42 6 23 14 115
2024/20252.905 6 116 28 128 366 349 233 147 269 441 310 512
2025/20263.027 209 315 205 158 379 358 556 126 204 372 77 68
2026/202760 60 0 0 0 0 0 0 0 0 0 0 0
Totale 14.775